Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(45%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
4
36%
Ph not_applicable
4
36%
Ph phase_3
1
9%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
1(9.1%)
N/ANon-phased studies
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Recruiting5
Completed3
unknown1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 31 (9.1%)
N/A4 (36.4%)

Trials by Status

completed327%
recruiting545%
unknown19%
not_yet_recruiting19%
withdrawn19%

Recent Activity

5 active trials
Showing 5 of 11
recruitingnot_applicable

Precision Radiotherapy Enabled by Molecular MRI

NCT07512154
recruitingphase_1

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

NCT06012695
recruitingphase_3

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

NCT06706401
recruitingphase_2

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

NCT06102057
not_yet_recruitingnot_applicable

Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

NCT07043543
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07512154Not Applicable

Precision Radiotherapy Enabled by Molecular MRI

Recruiting
NCT06012695Phase 1

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Recruiting
NCT06706401Phase 3

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Recruiting
NCT06102057Phase 2

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting
NCT07043543Not Applicable

Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

Not Yet Recruiting
NCT06276946Not Applicable

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia

Withdrawn
NCT06761937Phase 1

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Recruiting
NCT03750539Not Applicable

Chemotherapy and Pelvic Hypofractionated Radiation Followed by Surgery Cervical Cancer

Unknown
NCT02336165Phase 2

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Completed
NCT02107430Phase 2

Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer

Completed
NCT00796718Phase 2

A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer

Completed

All 11 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
11